Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Clinical Study on Tissue Preservation in Breast Augmentation and Reconstruction

28 maj 2026 uppdaterad av: Establishment Labs

Post-Marketing Clinical Follow-Up Study on Tissue Preservation Techniques in Breast Augmentation and Reconstruction.

This clinical study aims to evaluate the safety and effectiveness of advanced, minimally invasive techniques for breast augmentation and reconstruction. These methods, known as Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, and Maxtopexia + Mia, focus on preserving breast tissue, reducing recovery time, and improving aesthetic outcomes.

Studieöversikt

Detaljerad beskrivning

This post-marketing observational study evaluates the safety and efficacy of innovative, minimally invasive breast augmentation and reconstruction techniques: Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, and Maxtopexia + Mia. These techniques aim to enhance tissue preservation, minimize scarring, and promote quicker recovery compared to traditional methods.

The study will enroll 60 participants undergoing these procedures at the Sulàyöm Innovation Campus in Costa Rica between January and December 2025. Participants will be followed for 36 months to monitor complication rates, tissue health, and satisfaction. Procedures utilize advanced devices like the Motiva Ergonomix2® Diamond®, Motiva Injector®, Motiva® Inflatable Balloon, and Motiva® Reusable Channel Separator, designed to optimize outcomes while preserving natural breast structures.

Key assessments include:

Safety Metrics: Monitoring adverse events, such as tissue necrosis, hematoma, or infection, through regular follow-ups.

Efficacy Metrics: Evaluating tissue preservation during and after surgery using imaging and clinical assessments.

Patient and Surgeon Satisfaction: Measuring perceptions of outcomes and procedure success using validated scales.

The study will also conduct a temperature monitoring substudy using the Motiva® Zen transponder to assess its functionality in recording implant temperature. This optional component enhances understanding of implant safety.

Results will provide crucial insights into the role of minimally invasive techniques in improving breast surgery outcomes, focusing on safety, tissue preservation, and patient satisfaction. These findings will inform future surgical practices and technological advancements.

Studietyp

Observationell

Inskrivning (Beräknad)

60

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Alajuela Province
      • Coyol, Alajuela Province, Costa Rica, 20113
        • Establishment Labs

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The study population comprises approximately 60 cisgender women aged 18 years or older who will undergo minimally invasive breast augmentation or benign reconstruction procedures at the Sulàyöm Innovation Campus in Costa Rica.

Eligible participants will include women with breast cup sizes ranging from AA to C, classified as ASA I or II, and with sufficient breast tissue to support implant placement. The cohort will include individuals undergoing the following procedures:

  • Mia Harmonization
  • Mia Scarless Lift
  • Mia Reconstruction
  • Joy Dot
  • Maxtopexia + Mia Additionally, participants may have congenital or acquired breast conditions (e.g., amastia, tuberous breasts, asymmetry) and meet the specific inclusion criteria for these advanced minimally invasive techniques.

Recruitment will focus on women scheduled for surgery between January and December 2025, with follow-up spanning 36 months. Participants must reside in Costa Rica to ensure adherence to follow-up visits.

Beskrivning

Inclusion Criteria:

  1. Gender and Age: Cisgender women, aged 18 years or older.
  2. Surgical Procedure: Participants undergoing primary breast augmentation or benign reconstruction using the following minimally invasive procedures:

    • Mia Harmonization
    • Mia Scarless Lift
    • Mia Reconstruction
    • Joy Dot
    • Maxtopexia + Mia
  3. Breast Size: Cup sizes AA to C, as determined by guidelines from Triumph International.
  4. Health Status: ASA (American Society of Anesthesiologists) classification I or II.
  5. Tissue Integrity: Adequate breast tissue available to cover the implant(s).
  6. Commitment: Willingness to adhere to all study requirements, including follow-up visits and signing the informed consent form.
  7. Special Cases for Reconstruction: Participants with congenital or acquired breast or thoracic conditions, such as amastia, pectus excavatum/carinatum, tuberous breasts, or asymmetry.
  8. Mia Scarless Lift Specifics: Participants with mild, moderate, or pseudoptosis based on physician evaluation.
  9. Timing: Women scheduled for surgery at the Sulàyöm Innovation Campus between January and December 2025.

Exclusion Criteria:

  1. Non-Specified Procedures: Women undergoing augmentation or reconstruction with techniques other than those listed (Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, Maxtopexia + Mia).
  2. Non-Study Implants: Use of implants other than Motiva products.
  3. Compromised Tissue or Skin:

    • Existing rib lesions or significant/severe breast ptosis.
    • Poor tissue quality due to radiation damage, vascular compromise, or prior ulceration.
  4. Medical History:

    • History of breast abscesses or infections.
    • Sensitivity or allergy to silicone.
  5. Current Physiological Conditions:

    -Pregnancy or breastfeeding, or within six months postpartum or post-lactation.

  6. Medications: Use of anticoagulants or medications that impair wound healing (e.g., corticosteroids, Warfarin).
  7. Imaging Constraints: Conditions that prevent the use of MRI (e.g., implanted metal devices, claustrophobia).
  8. Concurrent Research: Participation in another clinical research study involving drugs or devices.
  9. Follow-Up Barriers: Residency outside Costa Rica or inability to attend required follow-up visits.
  10. Timing Issues: Participants undergoing surgery outside the designated study period (January to December 2025).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Minimally Invasive Breast Surgery Cohort
This single cohort consists of approximately 60 women undergoing one of the minimally invasive breast augmentation or reconstruction procedures (Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, or Maxtopexia + Mia) at the Sulàyöm Innovation Campus. Data from all participants will be analyzed collectively to evaluate the safety, efficacy, and outcomes of these procedures.
Minimally invasive technique for breast augmentation, increasing volume while preserving natural tissue.
Minimally invasive breast lift for mild to moderate ptosis without visible scarring.
Reconstructive technique for restoring breast contour and volume after benign surgical interventions.
Advanced augmentation method using specialized tools to preserve tissue integrity and minimize trauma.
Breast lift combining traditional techniques with advanced minimally invasive methods for tissue preservation.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of Adverse Events Related to Tissue Preservation
Tidsram: 36 months post-surgery.
The cumulative occurrence of adverse events, such as necrosis, hematoma, infection, or tissue damage, associated with the surgical procedures.
36 months post-surgery.
Rate of Intraoperative Tissue Integrity Preservation
Tidsram: Day of surgery.
Proportion (%) of surgical procedures in which intraoperative tissue integrity is maintained (no damage observed), and incidence rate (%) of tissue damage events during surgery, as assessed intraoperatively.
Day of surgery.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient-Reported Satisfaction Score (5-Point Likert Scale)
Tidsram: Baseline and follow-ups at 1, 3, 6, 12, 24, and 36 months post-surgery.
Mean score and distribution of patient-reported satisfaction with breast appearance, natural feel, and symmetry, measured using a 5-point Likert scale.
Baseline and follow-ups at 1, 3, 6, 12, 24, and 36 months post-surgery.
Surgeon-Reported Satisfaction Score (5-Point Likert Scale)
Tidsram: Day of surgery.
Mean score and distribution of surgeon-reported satisfaction with breast appearance, natural feel, and symmetry, measured using a 5-point Likert scale.
Day of surgery.
Rate of Postoperative Complications
Tidsram: 36 months post-surgery.
Incidence rate (%) of postoperative complications, including fibrosis, capsular contracture, and scarring, during the follow-up period.
36 months post-surgery.

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient-Reported Pain Score (Standardized Pain Scale)
Tidsram: Baseline and follow-ups at 1, 3, 6, 12, 24, and 36 months post-surgery.
Mean patient-reported pain score measured using a standardized pain scale at each follow-up visit.
Baseline and follow-ups at 1, 3, 6, 12, 24, and 36 months post-surgery.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 maj 2025

Primärt slutförande (Beräknad)

31 december 2026

Avslutad studie (Beräknad)

28 februari 2029

Studieregistreringsdatum

Först inskickad

20 augusti 2025

Först inskickad som uppfyllde QC-kriterierna

28 maj 2026

Första postat (Faktisk)

3 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual Participant Data (IPD) will not be shared to ensure the confidentiality and privacy of participants. Since the study collects sensitive clinical data, strict measures are in place to protect participant identities. Data will be securely stored in a de-identified and encrypted format, accessible only to authorized research personnel. This approach aligns with ethical standards and local regulations, such as Costa Rica's Ley de Investigación Biomédica (Law 9234), which prioritizes the protection of participants' personal information.

Additionally, as this is an observational study with no direct interventions, the value of sharing IPD for broader scientific purposes is limited compared to the aggregate analysis and results.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera